Although the Supplementary Figure S3 shows significantly increased expression of UBR5 and YWHAZ in the liver tumor group compared with the normal group from clinical samples, immunohistochemistry showed that UBR5 and YWHAZ were mainly localized in the nucleus, so these findings must be confirmed in clinical liver cancer patients as a further step. Here, UBR5 is linked to liver cancer.